- Report
- August 2026
- 183 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- August 2026
- 376 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- January 2026
- 180 Pages
Global
From €4042EUR$4,500USD£3,453GBP
- Report
- March 2026
- 149 Pages
Global
From €2694EUR$2,999USD£2,301GBP
€3592EUR$3,999USD£3,068GBP
- Report
- December 2025
- 150 Pages
Global
From €4356EUR$4,850USD£3,721GBP
- Report
- February 2026
- 144 Pages
Global
From €3548EUR$3,950USD£3,031GBP
- Report
- June 2026
- 200 Pages
Global
From €2686EUR$2,990USD£2,294GBP
- Report
- August 2026
- 198 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- January 2026
- 184 Pages
Global
From €3184EUR$3,545USD£2,720GBP
€3538EUR$3,939USD£3,022GBP
- Report
- April 2026
- 200 Pages
Global
From €2686EUR$2,990USD£2,294GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- August 2026
- 189 Pages
Global
From €5254EUR$5,850USD£4,488GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- February 2026
- 250 Pages
Global
From €4033EUR$4,490USD£3,445GBP
- Report
- January 2026
- 281 Pages
Global
From €2245EUR$2,500USD£1,918GBP
- Report
- October 2025
- 160 Pages
Global
From €2838EUR$3,160USD£2,424GBP
€3548EUR$3,950USD£3,031GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more